Compare SEER & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEER | AVXL |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.0M | 115.9M |
| IPO Year | 2020 | 2013 |
| Metric | SEER | AVXL |
|---|---|---|
| Price | $1.56 | $0.93 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 142.8K | ★ 1.0M |
| Earning Date | 11-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $1.55 | $0.98 |
| 52 Week High | $2.38 | $5.36 |
| Indicator | SEER | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 27.98 | 26.92 |
| Support Level | N/A | N/A |
| Resistance Level | $1.85 | $1.60 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 5.45 | 9.24 |
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.